Triple-Negative Breast Cancer Clinical Trial Tracker — Stay Current on ADCs, Immunotherapy, and BRCA Therapies

Why triple-negative breast cancer trial monitoring matters

Triple-negative breast cancer (TNBC) — defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression — accounts for approximately 15–20% of all breast cancers and disproportionately affects younger women and those of African descent. It carries the worst prognosis of the major breast cancer subtypes: higher rates of visceral metastasis, earlier relapse, and historically no targetable receptor to exploit.

The therapeutic landscape has transformed dramatically since 2019. The approval of pembrolizumab (Keytruda) in combination with chemotherapy for PD-L1-positive TNBC, the ADC sacituzumab govitecan (Trodelvy), and PARP inhibitors for BRCA-mutant disease have created multiple new standards of care — and triggered an explosion of combination and next-generation trials. Key signals to track:

• Antibody-drug conjugate (ADC) programs — new TROP2-targeting agents, novel payloads, and second-generation Trop-2 ADCs
• Checkpoint inhibitor + ADC combinations — the next frontier after pembrolizumab + chemotherapy
• Neoadjuvant immunotherapy trials — pembrolizumab combinations and competitors seeking pathological complete response improvement
• BRCA1/2 and PALB2 mutation-specific programs — PARP inhibitors in earlier treatment lines and combinations
• BRCA-adjacent targets: ATR inhibitors, WEE1 inhibitors, and DNA damage response pathway combinations
• HER2-low reclassification and ADC trials in ER-/HER2-low patients — a growing subtype
• Androgen receptor-positive TNBC (LAR subtype) — targeted endocrine approaches in a distinct molecular subtype

What we monitor for triple-negative breast cancer

Our pipeline pulls directly from the ClinicalTrials.gov API every day. For a TNBC watch profile, you can configure:

• Condition keywords: "triple negative breast cancer", "TNBC", "triple-negative breast cancer", "ER-negative breast cancer", "basal-like breast cancer", "BRCA1 breast cancer"
• Phase filter: Phase 1 only, Phase 2/3, or all phases
• Sponsor filter: Industry-sponsored only (for competitive intelligence) or all sponsors
• Status filter: Recruiting only, all active studies, or any status

The TNBC treatment landscape in 2026

Checkpoint immunotherapy: pembrolizumab and the competition

The KEYNOTE-522 trial established pembrolizumab (Keytruda, Merck) + chemotherapy as a standard of care in early-stage TNBC, demonstrating improved pathological complete response (pCR) rates and event-free survival in both PD-L1-positive and PD-L1-unselected populations. In the metastatic setting, KEYNOTE-355 supported use in PD-L1-positive disease (CPS ≥10). Atezolizumab + nab-paclitaxel previously held approval but was withdrawn after IMpassion131 failed — a cautionary tale in chemotherapy backbone selection.

The competitive response to KEYNOTE-522 has been substantial: multiple companies are registering neoadjuvant trials with anti-PD-1 and anti-PD-L1 agents in novel chemotherapy combinations, attempting to improve on or challenge pembrolizumab's early-stage efficacy. Monitoring these trials gives competitive visibility into the neoadjuvant landscape before data readouts.

ADCs: sacituzumab govitecan and the Trop-2 wave

Sacituzumab govitecan (Trodelvy, Gilead), an anti-Trop-2 ADC delivering SN-38 (the active metabolite of irinotecan), became the first ADC approved specifically in TNBC following the ASCENT trial's demonstration of survival benefit versus chemotherapy in pretreated metastatic disease. Its approval transformed the metastatic landscape and sparked a wave of follow-on ADC development.

Datopotamab deruxtecan (Dato-DXd, AstraZeneca/Daiichi Sankyo), a Trop-2-targeting ADC with a topoisomerase I inhibitor payload using Daiichi Sankyo's DXd technology, is advancing through Phase 3 trials in TNBC — including the TROPION-Breast02 trial in neoadjuvant setting. The head-to-head dynamics between sacituzumab govitecan and datopotamab deruxtecan will be determined over the next several years of trial readouts, making monitoring of new Trop-2 ADC trial registrations strategically important.

The ADC pipeline beyond Trop-2

TNBC's lack of HER2 expression historically excluded it from the HER2-directed ADC wave, but HER2-low reclassification — recognizing patients with IHC 1+ or IHC 2+/ISH-negative expression — has opened a new patient segment. Trastuzumab deruxtecan (Enhertu, AstraZeneca/Daiichi Sankyo) demonstrated significant benefit in HER2-low breast cancer across receptor subtypes, and TNBC patients who qualify as HER2-low may be eligible for this class. Patritumab deruxtecan (HER3-DXd), targeting HER3 which is expressed in a subset of TNBC, is also in clinical development. The ADC landscape in TNBC is expanding rapidly beyond the original Trop-2 framing.

PARP inhibitors and DNA damage response

Olaparib (Lynparza, AstraZeneca/Merck) and talazoparib (Talzenna, Pfizer) are approved in BRCA1/2-mutant HER2-negative breast cancer, with benefit most pronounced in TNBC given the lack of alternative targeted options. The OlympiA trial established olaparib as adjuvant therapy in BRCA-mutant early breast cancer with residual disease after neoadjuvant treatment — a significant expansion of the indication. PARP inhibitor combinations with immunotherapy, platinum chemotherapy, and AKT inhibitors are actively registering in TNBC, seeking to expand benefit beyond germline BRCA carriers.

Beyond PARP, the DNA damage response pathway is being targeted through ATR inhibitors (berzosertib, ceralasertib), WEE1 inhibitors (adavosertib and successors), and POLQ (Pol theta) inhibitors — all in clinical development as either monotherapy or combination strategies in BRCA-mutant or homologous recombination-deficient (HRD) TNBC.

Neoadjuvant trials: pCR as a surrogate and beyond

Neoadjuvant therapy in early TNBC provides a unique opportunity: pathological complete response (pCR) at surgery is associated with excellent long-term outcomes and serves as an accelerated approval endpoint. CREATE-X and KEYNOTE-522 demonstrated that residual disease after neoadjuvant therapy defines a high-risk population who benefit from post-neoadjuvant capecitabine or pembrolizumab maintenance respectively. New trials are exploring intensified neoadjuvant platforms, de-escalation approaches in excellent responders, and novel agents in the post-neoadjuvant residual disease setting.

Germline testing and BRCA-adjacent biomarkers

BRCA1/2 germline testing is now standard in all TNBC patients, and its results increasingly drive treatment decisions across multiple lines of therapy. PALB2, RAD51C, RAD51D, and other homologous recombination (HR) pathway genes are under investigation as biomarkers for PARP inhibitor sensitivity. HRD testing platforms (genomic instability scores) are being incorporated into trial eligibility criteria. Monitoring trials that use these biomarkers as selection criteria or endpoints captures the precision medicine direction of TNBC development.

Who uses TNBC trial monitoring

Breast oncologists and cancer centers

Medical oncologists at comprehensive cancer centers manage TNBC patients who frequently exhaust standard options quickly in the metastatic setting. Tracking new trial registrations allows these physicians to identify enrollment opportunities for appropriate patients, particularly in post-platinum and post-ADC settings where options are limited. Academic breast oncologists also monitor the neoadjuvant landscape to prepare for guideline changes as pivotal trial data mature.

ADC developers and biopharma BD teams

The ADC field is one of the most competitive in oncology, and TNBC is a primary battleground given its high unmet need and lack of targetable receptors via conventional approaches. Companies developing novel ADC payloads, linker technologies, or new antigen targets monitor TNBC trial registrations to understand the competitive landscape, identify partnership opportunities, and assess the market dynamics their programs will enter.

Biomarker researchers and diagnostics companies

The expanding role of PD-L1 CPS scoring, HER2-low reclassification, HRD testing, and germline BRCA analysis creates significant demand for validated companion and complementary diagnostics. Companies developing these assays monitor clinical trial registrations that incorporate their biomarkers — or competing biomarkers — as eligibility criteria or primary endpoints. Each new trial registration that mandates a specific assay represents a potential validation and commercialization opportunity.

Oncology-focused investors

Investors with exposure to ADC platforms (Gilead/Immunomedics, AstraZeneca/Daiichi Sankyo, Pfizer, and emerging ADC biotechs) monitor TNBC trial registrations to assess pipeline progression, competitive dynamics, and the pace of clinical development. Trial registrations for next-generation ADCs or novel combination approaches often represent the earliest public signal of a company's clinical strategy for key oncology assets.

Frequently asked questions

How current is the TNBC trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.

Can I track neoadjuvant and metastatic TNBC trials separately?

Yes. On the Pro plan ($149/month), you can create multiple search profiles. You might have one profile for neoadjuvant and early-stage TNBC trials, another for ADC programs in metastatic disease, and another for BRCA/HRD-targeted approaches — each delivering a focused daily digest.

Does this cover international TNBC trials?

ClinicalTrials.gov includes trials conducted internationally, so yes — global TNBC trials registered on the platform are included. Major industry-sponsored programs with US sites, including Phase 3 trials by AstraZeneca, Merck, Gilead, and Pfizer, are systematically registered here regardless of where trial sites are located globally.

How is this different from ClinicalTrials.gov alerts?

ClinicalTrials.gov offers basic RSS-style alerts without phase filtering, sponsor type filtering, or organized digest formatting. We provide filtered, labeled, and organized alerts — the intelligence layer on top of the raw registry data.

Can I include HER2-low breast cancer alongside TNBC in my monitoring?

Yes. You can add "HER2-low breast cancer" or "ER-negative HER2-low" as keywords to your profile to capture the HER2-low population that overlaps with the TNBC pipeline — particularly relevant for Trastuzumab deruxtecan programs and other ADCs with activity across breast cancer receptor subtypes.